Mogrify extends Series A financing to $46 million USD

FHS
October 2, 2023
10:56 am

Mogrify Limited (Mogrify®), a biopharmaceutical company transforming the lives of patients through a novel class of in vivo reprogramming therapies, announced today an additional $10 million USD closing of its Series A financing.

Biomarker discovery offers hope for aggressive breast cancer treatment

A new study led by Lund University in Sweden has solved a years-old mystery: which patients with aggressive breast cancer are helped by a targeted

December 4, 2024

Siegfried to acquire an early-phase CDMO in Wisconsin (US) to strengthen its Drug Substances service offering – Biotech Investments

Siegfried AG / Key word(s): Acquisition 12-Jun-2024 / 06:30 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely

June 13, 2024

Key enzyme identified as potential target for cancer treatment

During every moment of any living organism’s life, enzymes are at work. These crucial proteins support life through most biological processes, including metabolism, movement, respiration,

September 14, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.